Literature DB >> 12558336

Age-specific seroprevalence of poliomyelitis, diphtheria and tetanus antibodies in Spain.

I Pachón1, C Amela, F De Ory.   

Abstract

In 1996, a seroepidemiological study was undertaken in Spain, with the main aim of estimating the population's immunity against poliomyelitis, tetanus and diphtheria. A population-based cross-sectional study was conducted, covering the population aged 2-39 years. The sample was stratified by age and rural-urban environment, and informed consent obtained to take blood specimens from subjects attending phlebotomy centres. The study included 3,932 persons and the prevalence of antibodies against all three types of poliovirus exceeded 94% across all age groups. From a high of 96% in subjects under the age of 15 years, immunity against diphtheria steadily declined to a low of 32.3% in subjects aged 30-39 years. Similarly, tetanus antitoxin concentrations indicating basic protection were present in 98.9% of the under-14 years age group; thereafter, immunity declined, until reaching 54.6% in the 30-39 years age group.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12558336      PMCID: PMC2869915          DOI: 10.1017/s0950268802007781

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  10 in total

1.  The seroepidemiology of tetanus in Catalonia, Spain.

Authors:  A Domínguez; P Plans; J Costa; J Espuñes; N Cardeñosa; L Salleras; A Plasència
Journal:  Med Microbiol Immunol       Date:  2007-01-23       Impact factor: 3.402

2.  Role of routine and mass vaccination campaigns in immunization status of adolescents.

Authors:  M Isabel S Dinelli; Mauro Fisberg; Maria Isabel de Moraes-Pinto
Journal:  Eur J Pediatr       Date:  2006-10-28       Impact factor: 3.183

3.  U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020-February 2022.

Authors:  Amen Ben Hamida; Myrna Charles; Christopher Murrill; Olga Henao; Kathleen Gallagher
Journal:  PLOS Glob Public Health       Date:  2022-08-05

4.  The evaluation of anti-diphtheria toxoid antibodies in healthy population in Kon Tum, Vietnam: a population-based study.

Authors:  Tuan Van Le; Van Thi Tuyet Nguyen; Quan Hoang Nguyen; Tram Thi Thu Nguyen; Thuy Thi Ngoc Duong; Trang Thi Thuy Ly; Thanh Ngoc Pham; Vuong Loc Nguyen; Chien Chinh Vien
Journal:  IJID Reg       Date:  2022-04-01

5.  Seroprevalence of diphtheria toxoid IgG antibodies in children, adolescents and adults in Poland.

Authors:  Aleksandra A Zasada; Waldemar Rastawicki; Natalia Rokosz; Marek Jagielski
Journal:  BMC Infect Dis       Date:  2013-11-19       Impact factor: 3.090

Review 6.  Is EU/EEA population protected from polio?

Authors:  Dre Nijsten; P Carrillo-Santisteve; A Miglietta; J Ruitenberg; P L Lopalco
Journal:  Hum Vaccin Immunother       Date:  2015-04-21       Impact factor: 3.452

7.  Poliovirus antibody levels and lameness among individuals in three regions of Ghana.

Authors:  Joseph Kwadwo Larbi Opare; John Kofi Odoom; Patricia Akweongo; Edwin Andrew Afari; Matilda Pappoe
Journal:  Hum Vaccin Immunother       Date:  2019-07-25       Impact factor: 3.452

8.  Poliovirus neutralizing antibody levels among individuals in three regions of Ghana.

Authors:  Joseph Kl Opare; Patricia Akweongo; Edwin A Afari; John K Odoom
Journal:  Ghana Med J       Date:  2019-06

9.  Seroprevalence of an antibody against diphtheria, tetanus, and pertussis among the elderly in Khon Kaen, Thailand.

Authors:  Teeraporn Chinchai; Nawarat Posuwan; Viboonsak Vuthitanachot; Nasamon Wanlapakorn; Yong Poovorawan
Journal:  J Health Popul Nutr       Date:  2019-10-18       Impact factor: 2.000

10.  Factors determining anti-poliovirus type 3 antibodies among orally immunised Indian infants.

Authors:  Saravanakumar Puthupalayam Kaliappan; Srinivasan Venugopal; Sidhartha Giri; Ira Praharaj; Arun S Karthikeyan; Sudhir Babji; Jacob John; Jayaprakash Muliyil; Nicholas Grassly; Gagandeep Kang
Journal:  Vaccine       Date:  2016-08-24       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.